Kestra Private Wealth Services LLC Cuts Stock Position in Axon Enterprise, Inc $AXON

Kestra Private Wealth Services LLC cut its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 7.3% during the first quarter, Holdings Channel.com reports. The fund owned 15,788 shares of the biotechnology company’s stock after selling 1,239 shares during the period. Kestra Private Wealth Services LLC’s holdings in Axon Enterprise were worth $6,705,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Evergreen Capital Management LLC grew its position in shares of Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 15 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in Axon Enterprise by 0.5% in the 3rd quarter. Quadrant Capital Group LLC now owns 3,968 shares of the biotechnology company’s stock worth $2,848,000 after purchasing an additional 19 shares in the last quarter. CWA Asset Management Group LLC lifted its holdings in Axon Enterprise by 5.2% in the 4th quarter. CWA Asset Management Group LLC now owns 387 shares of the biotechnology company’s stock worth $220,000 after purchasing an additional 19 shares in the last quarter. Synergy Financial Group LTD boosted its stake in Axon Enterprise by 1.4% in the 3rd quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock worth $996,000 after purchasing an additional 19 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in Axon Enterprise by 1.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company’s stock worth $1,350,000 after purchasing an additional 19 shares during the period. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Trading Up 4.6%

Shares of NASDAQ AXON opened at $465.12 on Friday. Axon Enterprise, Inc has a fifty-two week low of $339.01 and a fifty-two week high of $885.91. The company has a market cap of $37.49 billion, a price-to-earnings ratio of 186.79, a PEG ratio of 8.09 and a beta of 1.45. The business’s 50 day moving average price is $420.65 and its 200-day moving average price is $482.08. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The business had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.90 million. During the same period in the previous year, the company posted $1.47 EPS. Axon Enterprise’s revenue was up 33.7% on a year-over-year basis. On average, sell-side analysts expect that Axon Enterprise, Inc will post 1.82 earnings per share for the current year.

Insiders Place Their Bets

In other Axon Enterprise news, CRO Cameron Brooks sold 1,242 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $500.00, for a total transaction of $621,000.00. Following the sale, the executive owned 49,710 shares in the company, valued at approximately $24,855,000. The trade was a 2.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Isaiah Fields sold 2,000 shares of the stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $400.00, for a total transaction of $800,000.00. Following the sale, the insider directly owned 52,813 shares in the company, valued at $21,125,200. This trade represents a 3.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 38,989 shares of company stock valued at $19,090,083. 4.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on AXON shares. Citizens Jmp reaffirmed a “market outperform” rating and set a $700.00 price objective on shares of Axon Enterprise in a report on Thursday. Piper Sandler restated an “overweight” rating and set a $674.00 target price on shares of Axon Enterprise in a research report on Monday, June 15th. Weiss Ratings raised shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Barclays reduced their price target on shares of Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, The Goldman Sachs Group set a $535.00 price target on shares of Axon Enterprise in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $712.75.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.